Albany Medical College

Albany Medical College, a private medical school and academic medical center headquartered in Albany, New York, is a tax-exempt nonprofit entity that operates as a prime recipient of federal research grants and clinical training contracts, alongside a small volume of sub-recipient work on externally managed grants. The institution competes in full-and-open federal procurement without set-aside designation, delivering biomedical research, clinical services, and military medical education and training to federal agencies.

Albany Medical College's federal footprint centers on investigator-initiated NIH research grants spanning infectious disease, cardiovascular health, neurology, aging, cancer biology, and emerging pandemic countermeasures. The college operates as a prime recipient across multiple NIH institutes and centers, including the National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Aging, National Heart, Lung, and Blood Institute (NHLBI), National Institute of Neurological Disorders and Stroke (NINDS), and National Cancer Institute. Representative recent grants include a $1.95 billion award from NINDS to investigate inflammation-resolution pathways in vascular cognitive impairment and dementia; a $1.634 million project grant from NHLBI on endothelial inflammation resolution in atherosclerosis progression and regression; and a $633 thousand NIAID award to study lung protective immunity from a parental Yersinia-vesicle vaccine against pneumonic plague, all with performance through 2028 or later. Smaller clinical training and services contracts flow from the Department of the Navy Bureau of Medicine and Surgery and Veterans Affairs for tuition and fees supporting military medical officer training and intensive care unit physician staffing; a $1.614 million fixed-price-with-economic-price-adjustment contract with Veterans Integrated Service Network 2 for intensive care unit physician services runs through June 2028.

Customer concentration sits heavily with the research enterprise. The Department of Veterans Affairs and its Veterans Health Administration component account for approximately 26 percent of recent awards by count (94 awards), anchored by Veterans Integrated Service Network 2 with 51 awards and $25.5 million in combined potential value. The National Institutes of Health and its subordinate institutes command 71 awards; NIAID alone represents 33 awards. The Department of the Navy Bureau of Medicine and Surgery holds 48 awards collectively valued at $5 million, primarily tuition and fees delivery orders for medical education. These three customer families account for 54 percent of all recent awards and 75 percent of combined potential value across the portfolio.

The college's research portfolio carries no parent IDIQs or GWACs; awards are issued as direct grants, project grants, and sub-recipient participation on larger institutional grants. Work is performed in Albany, New York at the college's campus and associated Albany Med Health System clinical facilities, with place of performance described across awards as Albany, NY. Activity has remained steady—13 to 27 awards annually over the past five years, with 27 awards issued in both 2024 and 2025—and 34 awards (combined potential value $1.6 million) reach ultimate completion within the next twenty-four months, creating moderate recompete exposure.

Albany Medical College acts as a sub-recipient on federal grants managed by prime grantees including Columbia University (for HIV provider training and education), Thomas Jefferson University (for cardiac hypertrophy mechanisms), the Research Foundation for the State University of New York (for organoid development and spinocerebellar ataxia research), and Rensselaer Polytechnic Institute (for vascular biology and tumor biomechanics work). Sub-award work involves clinical sample collection, investigator effort, and research coordination under larger R01 and related NIH awards. Rensselaer Polytechnic Institute serves as a sub-recipient on Albany's $648 thousand National Cancer Institute award to investigate tumor biomechanics and monoclonal antibody efficacy in HER2-positive breast cancer, providing research on drug-receptor engagement as a multiple principal investigator partner.

The Service Contract Inventory dataset records minimal SCI-reportable activity—five total records spanning FY2023 through FY2025, with zero invoiced revenue on prime service contracts above the $150,000 threshold and negligible FTE trajectory (0.1 FTEs in FY2025). This reflects the institution's grant-and-contract research profile, which sits outside typical SCI capture for service-delivery contracts. The college's federal revenue model centers on research grants, training contracts, and clinical services reimbursement rather than on billable-hour service contract work.